06.26.26 -- Optimizing Your Sterile Fill-Finish Network: Capacity, Compliance, And Scaling

Patricia Krainski highlights global sterile fill‑finish and lyophilization strengths, showcasing investments that expand capacity, technologies, and integrated solutions for complex biologics, formulations, and lyophilized products.

By partnering with us, you gain access to our unique, interconnected network, purpose-built to overcome the breakpoints common in traditional manufacturing models.

A look at sterile injectable expansion highlighting investment, advanced fill‑finish technologies, and flexible manufacturing from development to commercial production.

Delve into a modern Annex 1–compliant sterile facility designed for flexible aseptic and terminally sterilised manufacturing across multiple drug delivery routes.

A streamlined process development and preclinical manufacturing framework in India optimizes early-phase drug candidates, accelerating timelines and reducing costs before transitioning to clinical-scale production.

With industry-leading viral expertise, we navigate the rapidly evolving field of virotherapy to support the development and manufacturing of your gene therapies, viral vector vaccines and oncolytic viruses (OVs).

High productivity rate using advanced inspection technologies. CVT inspection machines promise to deliver high-speed, high-performance inspection of a wide range of drugs.